What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cholesterol
Anton F. H. Stalenhoef spends much of his time researching Internal medicine, Endocrinology, Cholesterol, Familial hypercholesterolemia and Apolipoprotein B.
As a part of the same scientific family, Anton F. H. Stalenhoef mostly works in the field of Internal medicine, focusing on Gastroenterology and, on occasion, Lipid profile.
Hypertriglyceridemia, Triglyceride, Diabetes mellitus, Hyperlipidemia and Insulin resistance are the core of his Endocrinology study.
His research investigates the connection between Cholesterol and topics such as Vascular disease that intersect with issues in Cross-sectional study, Plasma levels and Cholesterol lowering.
Anton F. H. Stalenhoef combines subjects such as Ezetimibe, Xanthoma and Genetic testing with his study of Familial hypercholesterolemia.
His Apolipoprotein B research incorporates themes from Absorbance, Lathosterol, Butylated hydroxytoluene and Low-density lipoprotein.
His most cited work include:
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society (1430 citations)
- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia (1069 citations)
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (534 citations)
What are the main themes of his work throughout his whole career to date?
Anton F. H. Stalenhoef mainly focuses on Internal medicine, Endocrinology, Cholesterol, Lipoprotein and Apolipoprotein B.
In his study, which falls under the umbrella issue of Internal medicine, Surgery is strongly linked to Cardiology.
His study in Very low-density lipoprotein, Low-density lipoprotein, Triglyceride, Insulin resistance and Hyperlipidemia is carried out as part of his studies in Endocrinology.
His studies in Cholesterol integrate themes in fields like Gastroenterology and Vascular disease.
His research on Lipoprotein frequently connects to adjacent areas such as Immunology.
His Apolipoprotein B research is multidisciplinary, relying on both Genetics, Apolipoprotein E and Lipoprotein lipase, Hepatic lipase.
He most often published in these fields:
- Internal medicine (67.80%)
- Endocrinology (54.17%)
- Cholesterol (29.55%)
What were the highlights of his more recent work (between 2007-2016)?
- Internal medicine (67.80%)
- Endocrinology (54.17%)
- Disease (10.23%)
In recent papers he was focusing on the following fields of study:
Anton F. H. Stalenhoef spends much of his time researching Internal medicine, Endocrinology, Disease, Cholesterol and Familial hypercholesterolemia.
His Internal medicine study frequently intersects with other fields, such as Cardiology.
His Endocrinology study deals with Rheumatology intersecting with High-density lipoprotein and Tumor necrosis factor alpha.
His study on Disease also encompasses disciplines like
- Placebo most often made with reference to Gastroenterology,
- Physical therapy which connect with Intensive care medicine, Statin, Asymptomatic, Pulse wave velocity and Stroke.
The concepts of his Cholesterol study are interwoven with issues in Dyslipidemia and Rheumatoid arthritis.
His Familial hypercholesterolemia research includes elements of Ezetimibe, Simvastatin, Atorvastatin and Pediatrics.
Between 2007 and 2016, his most popular works were:
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society (1430 citations)
- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia (1069 citations)
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (534 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cholesterol
Anton F. H. Stalenhoef mostly deals with Internal medicine, Endocrinology, Cholesterol, Familial hypercholesterolemia and Disease.
His research in Endocrinology tackles topics such as Inflammation which are related to areas like Foam cell and Macrophage.
He studies Lipoprotein, a branch of Cholesterol.
His research in Lipoprotein intersects with topics in ANGPTL4, Apolipoprotein E and Low-density lipoprotein.
Within one scientific family, he focuses on topics pertaining to Ezetimibe under Familial hypercholesterolemia, and may sometimes address concerns connected to Pediatrics and Surgery.
The Disease study combines topics in areas such as Genome-wide association study, Intensive care medicine, Treatment goals and Apolipoprotein B.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
